Novo Nordisk A/S (NYSE:NVO) Position Reduced by Cwm LLC

Cwm LLC reduced its position in shares of Novo Nordisk A/S (NYSE:NVO) by 3.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 105,834 shares of the company’s stock after selling 4,352 shares during the quarter. Cwm LLC’s holdings in Novo Nordisk A/S were worth $10,949,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. International Assets Investment Management LLC lifted its position in Novo Nordisk A/S by 133.2% in the 3rd quarter. International Assets Investment Management LLC now owns 7,837 shares of the company’s stock worth $719,000 after buying an additional 4,476 shares in the last quarter. AE Wealth Management LLC raised its holdings in shares of Novo Nordisk A/S by 142.8% during the third quarter. AE Wealth Management LLC now owns 26,888 shares of the company’s stock worth $2,445,000 after acquiring an additional 15,812 shares in the last quarter. IFP Advisors Inc boosted its position in Novo Nordisk A/S by 61.6% during the third quarter. IFP Advisors Inc now owns 4,244 shares of the company’s stock valued at $386,000 after purchasing an additional 1,618 shares during the last quarter. Arkadios Wealth Advisors boosted its position in Novo Nordisk A/S by 99.5% during the third quarter. Arkadios Wealth Advisors now owns 3,671 shares of the company’s stock valued at $334,000 after purchasing an additional 1,831 shares during the last quarter. Finally, RFG Advisory LLC increased its position in Novo Nordisk A/S by 90.1% in the 3rd quarter. RFG Advisory LLC now owns 7,039 shares of the company’s stock worth $640,000 after purchasing an additional 3,336 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 2.1 %

Shares of NVO stock opened at $125.23 on Tuesday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82. The firm has a fifty day moving average of $126.49 and a 200-day moving average of $111.28. Novo Nordisk A/S has a 52-week low of $75.56 and a 52-week high of $138.28. The stock has a market cap of $561.97 billion, a price-to-earnings ratio of 46.30, a P/E/G ratio of 2.05 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The firm had revenue of $9.51 billion during the quarter, compared to analysts’ expectations of $9.14 billion. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were issued a dividend of $0.664 per share. The ex-dividend date was Friday, March 22nd. This represents a yield of 0.9%. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s payout ratio is currently 49.17%.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on NVO shares. BMO Capital Markets began coverage on Novo Nordisk A/S in a report on Friday, April 12th. They set an “outperform” rating and a $163.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target on the stock. Finally, UBS Group initiated coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating for the company. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.